Trial Profile

A Phase I Open-label, Dose-escalation Trial of PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-CD7 chimeric antigen receptor T-cell therapy-PersonGen Biomedicine (Primary)
Indications Haematological malignancies; Precursor T-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions
Sponsors PersonGen Biotherapeutics

04 Jun 2024 Results (n=12, data cut off: Nov 28th, 2023) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
12 Dec 2023 Preliminary safety and efficacy data for PA3-17 injection in adult r/r T-ALL/LBL patients in a Phase I clinical study presented at the 65th American Society of Hematology Annual Meeting and Exposition
29 Apr 2022 According to a PersonGen Biotherapeutics media release, first patient has been infused and treated with PA3-17 in this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com